Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab phase 2/3 study in moderately to severely active Crohn's disease
2023-504736-18-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in Crohn's Disease Activity Index score at Week 12, Clinical response at Week 12 and clinical remission at Week 48 and 3 more. Planned start Jul 2018; status: authorised.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-504736-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504736-18-00.